03.07.2024 10:30:06 - dpa-AFX: GNW-Adhoc: Olon Group Announces the Acquisition of GTP Bioways Group
MILAN, July 03, 2024 (GLOBE NEWSWIRE) -- GTP Bioways Group is a French company
operating as Biotech CDMO (Contract Developing and Manufacturing Organisation),
specialising in R&D Services, process development and production of mAbs,
enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways Group, with multiple
locations across France, specializes in delivering comprehensive services to
biopharmaceutical companies. From preclinical development to commercial stages,
the group focuses on utilizing cutting-edge technologies to advance innovative
therapies.
GTP Bioways Group's services are seamlessly integrated with those of the Olon
Biotech division. This integration enables Olon Biotech to expand and diversify
its technological offerings, supporting every stage of the lifecycle, from R&D
and preclinical phases to industrialization, through microbial and mammalian
fermentation and biotherapeutics. Additionally, Olon Biotech will provide
comprehensive services for the development and production of innovative ADC
classes, offering a complete solution from mAbs to linkers, payloads,
conjugation, and fill-and-finish processes.
GTP Bioways operates a total of four sites in France (Toulouse, Labege, Veyre-
Monton, and Saint-Julien-en-Genevois) focused on development, clinical trial and
cGMP manufacturing. The headquarters are based in Toulouse.
The four centers operate according to the highest quality standards, in line
with reference GMPs and are regularly inspected by the relevant regulatory
authorities.
The business areas on which GTP Bioways focuses include biologics manufacturing
and ADC manufacturing (using mammalian and microbial fermentation technology),
nanodrug manufacturing, fill and finish and analytical development - including
HCP and immuno assay. In particular, the company has consolidated a strong
expertise in the business areas in which it operates. Evidenced by a
significative number of successfully developed biological processes, the
management of a broad and diversified range of expression systems (mammalian,
bacterial, yeast, insect cells) and molecules (mAbs, antibody fragments,
cytokines, fusion proteins, enzymes, antigens). In addition, the group possesses
significant expertise in bioconjugation and fill & finish. The CDMO services
offered make up an integrated platform capable of supporting customers from drug
discovery, through the entire development process with a special focus on the
pre-clinical phase, phase I and phase II.
Since its foundation, Olon Group has consistently pursued a strategy of growth,
consolidation, and global market expansion through both internal development and
strategic acquisitions. Each acquired business has contributed valuable
expertise, enhancing Olon's technological capabilities. In line with this
strategy and aiming to advance its innovative and high-tech offerings to
customers, Olon has acquired GTP Bioways Group. GTP Bioways Group's specific
capabilities in fully supporting CDMO biotechnology projects also in the early
phase of new molecule development (pre-clinical, phase I and phase II),
perfectly complements Olon's current assets, to enrich and broaden the offering
to customers.
"The acquisition of GTP Bioways Group implies a strong and significant
strengthening of Olon's service pipeline with the aim of creating new business
opportunities, acquiring new customers and high-potential market areas, and
ultimately continuing the company's growth," stated Paolo Tubertini, CEO, Olon
Group.
In Q3 2024, Olon will finalise its EUR25m investment in a facility operating under
extremely high containment, fully dedicated to the development and the
production of Ultra High Potent API - payloads and payload-linkers for antibody-
drug conjugates (ADCs). Olon relies on more than four decades of experience in
manufacturing cytotoxic products. With the acquisition of GTP Bioways, Olon
Biotech will be able to offer full services for the development and production
of ADCs, capable of supplying everything from mAbs to linkers, payloads,
conjugation and fill and finish.
Contact info - Sabrina Spina, Olon Press Office. sspina@olonspa.it /
+39 338 6674289
Â